Used in pharmaceutical research as an intermediate in the synthesis of kinase inhibitors, particularly for targeted cancer therapies. Its structure supports modification for optimizing potency and selectivity in drug candidates. Commonly employed in the development of small-molecule inhibitors that modulate signaling pathways involved in tumor growth and progression. Also utilized in studies involving nucleoside analogs and antiviral agents due to its resemblance to purine scaffolds. The silyl-protected group allows for selective deprotection and further functionalization during multi-step syntheses.